Amazon's Fee Hike and Pharma Foray Set Stage for Critical Earnings

Amazon stock gains as new 3.5% seller fees, expansion of Eli Lilly drug delivery, and a $15B AI revenue run rate from AWS shape its complex Q1 2026 outlook.

Amazon shares closed Friday's session up roughly two percent, trading at $238.38 and solidly above their 200-day moving average of $193.25. This resilience comes as the e-commerce giant navigates a complex landscape where burgeoning opportunities in cloud computing and healthcare intersect with mounting cost pressures in its core retail operations.

A significant new cost wave is set to hit the company's vast online marketplace. Effective April 17, Amazon will impose a 3.5 percent surcharge on logistics and fulfillment fees for third-party sellers in the US and Canada. This move impacts approximately two million merchants at a precarious time, as many have depleted inventory buffers built on management's advice and now face the need to pass higher tariff-related supply chain costs directly to consumers.

Simultaneously, Amazon is advancing its push into the lucrative healthcare sector. Through Amazon Pharmacy, the company has begun direct-to-home delivery of Eli Lilly's newly FDA-approved GLP-1 drug, Foundayo (Orforglipron). The oral medication, which is stable at room temperature, offers a significant logistical advantage over injectable rivals. Amazon currently serves about 3,000 U.S. cities with plans to expand to 4,500 locations by year-end 2026, also distributing the drug via kiosks in its One Medical clinics. Pricing is set at $25 per month for insured patients and $149 for those paying out-of-pocket.

The optimism supporting the stock price is largely fueled by the cloud division, AWS. In his annual shareholder letter, CEO Andy Jassy revealed that AWS has achieved an annualized revenue run rate of $15 billion from AI services alone. The broader business related to Amazon's custom chips has reached $20 billion, with internal estimates suggesting potential growth to $50 billion. To support this expansion, the company is channeling roughly $25 billion into new data center capacity.

However, this growth narrative faces tangible headwinds. Beyond the marketplace fee increase, Amazon is contesting a major legal setback. The National Labor Relations Board (NLRB) has ordered the company to formally recognize the union at its JFK8 warehouse in Staten Island and begin collective bargaining. Amazon plans to appeal the order to a federal appeals court. A final ruling could set a precedent for unionization efforts at other facilities.

Investor positioning reflects this mixed outlook. In the fourth quarter of 2025, Highline Wealth Partners increased its stake by 7.4 percent, while corporate insiders sold shares worth approximately $14.9 million.

All these threads will converge at the end of April when Amazon reports its first-quarter 2026 results. The key question for investors will be whether AWS can sustain its growth rate above 20 percent. A slowdown could force a reassessment of the company's valuation, which is heavily predicated on cloud acceleration. The coming weeks, framed by the new seller fees, ongoing legal battles, and macroeconomic retail data, will define the fundamental backdrop for those crucial earnings.